Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HDL Cholesterol Clear all
Recruiting Not applicable Interventional

Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food

NCT06988462
View directory record Official record
Conditions
Prediabetes, Diabetes, High Cholesterol/Hyperlipidemia, Obesity & Overweight, Triglycerides, HDL Cholesterol
Interventions
Bottarga, Comparator
Other
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sommerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 4:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Niaspan on Cholesterol in Men

NCT00765284
View directory record Official record
Conditions
HDL Cholesterol
Interventions
Not listed
Lead sponsor
KineMed
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Jul 23, 2026, 4:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux

NCT04061018
View directory record Official record
Conditions
Lipid Metabolism Disorders
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional

Antihyperlipidemic Effects of Oyster Mushrooms

NCT00069524
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia
Interventions
oyster mushroom
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2007 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

NCT00326326
View directory record Official record
Conditions
Dyslipidemia
Interventions
CP-778,875
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
31
States / cities
Anniston, Alabama • Huntsville, Alabama • Greenbrae, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 6, 2009 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

NCT01487460
View directory record Official record
Conditions
Dyslipidemia, Healthy Volunteers
Interventions
TAP311
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jul 23, 2026, 4:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

NCT01753674
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
TA-65, Placebo
Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Not applicable Interventional

Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness

NCT02180841
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Soy Protein Powder (25g/d), Placebo, Soy Protein Powder (50g/d)
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
35 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 23, 2026, 4:04 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Quercetin on Metabolic Health

NCT05297032
View directory record Official record
Conditions
Quercetin, Lipid Metabolism, Aging
Interventions
Quercetin Phytosome
Dietary Supplement
Lead sponsor
Thorne HealthTech, Inc
Industry
Eligibility
20 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Summerville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

NCT01262118
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 (tasocitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
9
States / cities
Anniston, Alabama • Little Rock, Arkansas • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Jul 23, 2026, 4:04 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism

NCT01199211
View directory record Official record
Conditions
Left Ventricular Hypertrophy
Interventions
Exercise training, women, marathon
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Not applicable Interventional

A Whole Food Plant Diet and Its Lipidemic Effects on Primary Prevention in a Free-range Population

NCT03523247
View directory record Official record
Conditions
Diet Modification, Cardiology
Interventions
whole food, plant based diet
Behavioral
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 on Pharmacokinetics in Healthy Participants

NCT01448824
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2484595, Placebo, Ketoconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

NCT01426438
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Niacin, Aspirin, Fenofibrate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Corn and Heart Health Study

NCT03967990
View directory record Official record
Conditions
Gut Microbiome, Cholesterol, LDL, Cholesterol, HDL
Interventions
Refined cornmeal flour, 50/50 refined cornmeal-bran mix, Whole grain cornmeal flour
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 3 Interventional

The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol

NCT00283335
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
gemfibrozil, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Up to 73 Years · Male only
Enrollment
2,531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 2 Interventional

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

NCT01058018
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Not applicable Interventional

Metabolic Effects of Alcohol

NCT00167115
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Alcohol
Drug
Lead sponsor
Bantle, John P., MD
Individual
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

NCT00768274
View directory record Official record
Conditions
Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions
RVX000222, Placebo
Drug
Lead sponsor
Resverlogix Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 4 Interventional

Benefit of Elevation of HDL-C in Women

NCT01921010
View directory record Official record
Conditions
Cardiovascular Outcomes
Interventions
Niaspan, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

NCT00300365
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pioglitazone, Placebo, Niacin ER, Aspirin
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 1 Interventional

Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

NCT01554800
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis
Interventions
ACP-501
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
30 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Phase 2 Interventional Results available

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

NCT00504829
View directory record Official record
Conditions
Dyslipidemia
Interventions
LCP-AtorFen, atorvastatin, fenofibrate
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Jul 23, 2026, 4:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Habitual Diet and Avocado Trial

NCT03528031
View directory record Official record
Conditions
Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol, Triglycerides High, Diet Habit, High Blood Sugar, Liver Fat, Dietary Modification, HDL Cholesterol, Low Serum, Cardiovascular Diseases, High Density Lipoprotein Deficiency, Low-density-lipoprotein-type, Cardiovascular Risk Factor, Diabetes
Interventions
Intervention Daily Avocado
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years and older
Enrollment
1,008 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Loma Linda, California • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 23, 2026, 4:04 PM EDT